In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains
about
Treatment of gonorrhea: comparison of cefotaxime and penicillinEvaluation of aztreonam in experimental bacterial meningitis and cerebritis.Comparison of cefoperazone with penicillin, ampicillin, gentamicin, and chloramphenicol in the therapy of experimental meningitis.Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiencyMoxalactam and cefazolin: comparative pharmacokinetics in normal subjects.Susceptibility of Neisseria gonorrhoeae to cefotaxime and ceftizoxime.Single 1 g dose of cefotaxime in the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeaeEffect of penicillin and spectinomycin given for urethritis and cervicitis with Neisseria gonorrhoeae: high prevalence of penicillin-resistant isolatesA comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Comparative study of cefoperazone and spectinomycin for treatment of uncomplicated gonorrhea in men.Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporinIn vitro evaluation of A-56619 and A-56620, two new quinolones.Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilliPharmacokinetics of cefoperazone in patients with neoplastic disease.Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.Comparative in vitro activity of cefmenoxime, cefotaxime, cefuroxime, cefoxitin, and penicillin against Neisseria gonorrhoeaeCefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeaeIn vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugsIn vitro antimicrobial susceptibility of penicillinase-producing and intrinsically resistant Neisseria gonorrhoeae strainsIn vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.In vitro susceptibility of 50 non-beta-lactamase-producing Neisseria gonorrhoeae strains to 12 antimicrobial agents.Pericarditis caused by beta-lactamase-producing Haemophilus influenzae: report of two cases in adults and review of the literatureTentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazoneCefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzaeSusceptibility of Haemophilus influenzae to chloramphenicol and eight beta-lactam antibiotics.Antimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime.Influence of growth medium and supplement on growth of Haemophilus influenzae and on antibacterial activity of several antibiotics.In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila.Influence of inoculum size on comparative susceptibilities of penicillinase-positive and -negative Neisseria gonorrhoeae to 31 antimicrobial agents.The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.
P2860
Q28366122-FE6A8EB1-5290-4620-8384-6711955A596AQ30451337-EF2C922B-C51B-4284-8A91-2DC078581AB3Q30451358-76D9137C-C7EB-4AB6-8712-4C8807D7A124Q30451377-B4744F8C-503B-4AE3-82A7-81C5417A7E34Q30451386-F6777E23-A00E-438C-BDC1-2529381EC890Q30451388-C581D747-218E-41EE-9DDC-72B6C2582249Q33658114-AF7BF5D0-B51B-4930-A504-A33AE1EA2E3EQ33659362-AFEB9456-51CA-4073-915F-B4D1A0894D31Q33932305-C6BB120C-0842-48BB-ACAA-138C89D7BD37Q34707883-F73DF7DF-B2A5-47C8-A0C0-FA53BF06ED5FQ35575504-BACBE99E-A039-474A-A2E2-6221E4B8C308Q35643730-4AF26A70-2BE3-4621-B9D9-6267AAEE8C3CQ35648314-531CE9BA-7937-4FA7-AC3A-6B7E7F9F1CB1Q35668711-AF025A8A-BEB6-419F-9F65-8F23C68D3705Q35670676-42287E8D-B503-4E6B-BC58-2D301DDF98E4Q35671269-CF065707-542D-4A55-AB93-1B4944A977BCQ35672296-ADE0D2B2-0700-4D8C-AAA6-57F1737298C8Q35672598-134B8D6C-4B14-4B41-BB23-FB435E352ED1Q35740391-F9B4E86A-0912-4576-B0F6-D0024ECF68FDQ35749382-49D6E53F-AA27-4AFB-9E18-13F43F4E2462Q35755259-179BBCF4-5D2E-479F-9013-E1570CE02AB4Q35760623-CC22D236-D4E5-4AC1-A4F9-D50E34810105Q35761288-B7C1C829-495C-44F4-AFCB-F3AE46F49781Q35769597-EAFEA1FC-5C29-432A-8E35-834813A8F0A4Q35822798-73B6FE31-6A23-4C6C-8D43-00229DA750F2Q37203973-4A97546D-95A7-4F62-AAD5-893C50A4FD4DQ37213740-8F0CDF4D-B08E-47FB-A722-C0554CB41585Q37291912-545CBD41-6725-4860-A7FE-D2074AFB6779Q37291928-59079B25-A7C0-463E-89BF-73B9068A8AB4Q39854642-25CE8B76-4128-434E-96A6-292291B28CF6Q39855256-C40B5D6E-DD3A-43F7-84D9-E7B3A780219BQ39855431-D08115AC-F601-4C22-AE55-D684F49738ADQ39855565-A62379BA-E228-469D-9776-B7F41E881040Q40114571-54E6FC25-9B7D-4DE1-9B1B-75FED2266E89Q40134639-F0C537C5-67EF-4F41-B735-6CE7EDD77F2FQ40190272-18D52CA8-BA22-4A11-9993-740DF3C56725Q40282852-4AFCB8E0-3C8D-4F71-8D60-1E440570FCFEQ40283286-2A0F7F57-BFA6-469E-9C07-8FA5FCD4CE2FQ40584325-21BEF400-E579-46F8-A807-5BB11342ECC7
P2860
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains
description
1980 nî lūn-bûn
@nan
1980 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@ast
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@en
type
label
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@ast
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@en
prefLabel
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@ast
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@en
P2093
P2860
P356
P1476
In vitro antimicrobial activit ...... ta-lactamase-producing strains
@en
P2093
P2860
P304
P356
10.1128/AAC.17.4.757
P407
P577
1980-04-01T00:00:00Z